scispace - formally typeset
P

Paul Bourgine

Researcher at Lund University

Publications -  102
Citations -  6924

Paul Bourgine is an academic researcher from Lund University. The author has contributed to research in topics: Mesenchymal stem cell & Stem cell. The author has an hindex of 28, co-authored 99 publications receiving 6376 citations. Previous affiliations of Paul Bourgine include University Hospital of Basel & Université Paris-Saclay.

Papers
More filters

From Molecules to Organisms: Towards Multiscale Integrated Models of Biological Systems

TL;DR: The aim of this collective paper is to provide a starting point for further discussions and interactions within the community of complex systems biologists, and present four major challenges that should be tackled in the next years.
Posted Content

Bounded rationality modeling

TL;DR: In this article, the authors deal with bounded rationality as a way to describe behavior and focus on the question of how to build such boundedly rational models, and discuss the reasons why such models are needed and on the situations in which they can be regarded as more particularly useful.
Journal ArticleDOI

$3D+t$ Morphological Processing: Applications to Embryogenesis Image Analysis

TL;DR: The proposed processing paradigm produces spatio-temporal coherent results as it benefits from the intrinsic redundancy of the temporal dimension, and minimizes the needs for human intervention in semi-automatic algorithms.
Journal ArticleDOI

Engineered humanized bone organs maintain human hematopoiesis in vivo.

TL;DR: It is reported that human ossicles in immunodeficient mice maintain human immature and mature hematopoiesis in vivo, and a higher percentage of human stem and progenitor cells are kept in quiescence in human Ossicles as compared with mouse BM.
Journal ArticleDOI

Culturing patient-derived malignant hematopoietic stem cells in engineered and fully humanized 3D niches

TL;DR: In this article, a 3D O-N was constructed for malignant CD34+ cells from acute myeloid leukemia (AML) and myeloproliferative neoplasm patients for up to three weeks.